Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 1004-1011

  Tolcher, A W ^a,b   Gerson, S L ^c   Denis, L ^a   Geyer, C ^d   Hammond, L A ^a,b   Patnaik, A ^a,b   Goetz, A D ^a   Schwartz, G ^e   Edwards, T ^a   Reyderman, L ^f   Statkevich, P ^f   Cutler, D L ^f   Rowinsky, E K ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b The University of Texas Health Science Center at San Antonio   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Joe Arrington Cancer Center   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GUANINE DERIVATIVE; ISOENZYME; SCH 52365; TEMOZOLOMIDE; TRANSFERASE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; ENZYME INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 0037692954     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600827     Document Type: Article

References (36)

1. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488
2. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367
3. Denis LJ, Tolcher A, Figueroa JA, Drengler R, Geyer C, Eckhardt SG, Cutler DI, Reyderman L, Von Hoff DD, Rowinsky EK (2000) Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic - pharmacodynamic study. Proc Am Soc Clin Oncol 19: 202a
4. Dolan ME, Moschel RC, Pegg AE (1990) Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Nat Acad Sci USA 87: 5368-5372
5. Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL (1989) Increase in nitrosourea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res 49: 6044-6051
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354
7. Figueroa JA, Tolcher A, Denis LJ, Drengler R, Geyer C, Eckhardt SG, Cutler DL, Reyderman L, Von Hoff DD, Rowinsky EK (2000) Protracted cyclic administration of temozolomide is feasible: a phase I pharmacokinetic and pharmacodynamic study. Proc Am Soc Clin Oncol 19: 222a
8. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857
9. Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M (1999) Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10: 831-838
10. Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C (1996) Human CD34+ haematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 88: 1649-1655
11. Hickman JA, Stevens MF, Gibson NW, Langdon SP, Fizames C, Lavelle F, Atassi G, Lunt E, Tilson RM (1985) Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res 45: 3008-3013
12. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310-3315
13. Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, Nomeir AA (2001) High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 24: 461-468
14. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE (2001) Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7: 421-428
15. Lee SM, Margison GP, Woodcock AA, Thatcher N (1993a) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 67: 1356-1360
16. Lee SM, Thatcher N, Crowther D, Margison GP (1994) Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69: 452-456
17. Lee SM, Thatcher N, Dougal M, Margison GP (1993b) Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67: 216-221
18. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP (2000) O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88: 469-473
19. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP, Thatcher N (1998) O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 78: 1199-1202
20. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
21. Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JEd, Trump DL (1992) Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res 52: 2456-2459
22. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129
23. Philip PA, Souliotis VL, Harris AL, Salisbury A, Tates AD, Mitchell K, van Delft JH, Ganesan TS, Kyrtopoulos SA (1996) Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin Cancer Res 2: 303-310
24. Schold Jr SC, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P (1989) O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70: 573-577
25. Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, Kirkwood JM (1996) Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2: 1129-1134
26. Spiro TP, Gerson SL, Liu L, Majka S, Haaga J, Hoppel CL, Ingalls ST, Pluda JM, Willson JK (1999) O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59: 2402-2410
27. Spiro TP, Krishnamurthi S, Burris HA, Modiano M, Kalman LA, Blair S, Zaknoen S (2001) A phase II study of an extended dosing schedule of temozolomide (TMZ) in metastatic colorectal carcinoma. Proc Am Assoc Clin Oncol 20: 124b
28. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
29. Tano K, Shiota S, Collier J, Foote RS, Mitra S (1990) Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Nat Acad Sci USA, 87: 686-690
30. Tsang LL, Farmer PB, Gescher A, Slack JA (1990) Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26: 429-436
31. Tsang LL, Quarterman CP, Gescher A, Slack JA (1991) Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharrnacol 27: 342-346
32. Walter CA, Zhou ZQ, Manguino D, Ikeno Y, Reddick R, Nelson J, Intano G, Herbert DC, McMahan CA, Hanes M (2001) Health span and life span in transgenic mice with modulated DNA repair. Ann NY Acad Sci 928: 132-140
33. Wedge SR, Porteous JK, Newlands ES (1997) Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40: 266-272
34. Willson JK, Haaga JR, Trey JE, Stellato TA, Gordon NH, Gerson SL (1995) Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J Clin Oncol 13: 2301-2308
35. Wu ZN, Chan CL, Eastman A, Bresnick E (1992) Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res, 52: 32-35
36. Zhou ZQ, Manguino D, Kewitt K, Intano GW, McMahan CA, Herbert DC, Hanes M, Reddick R, Ikeno Y, Walter CA (2001) Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc Nat Acad Sci USA 98: 12566-12571